10 Health Care Stocks Whale Activity In Today's Session
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
Earnings Call Summary | Axsome Therapeutics(AXSM.US) Q1 2025 Earnings Conference
Axsome Targets FDA Decision on AXS-14 for Fibromyalgia in Q2 2025
Earnings Call Summary | TG Therapeutics(TGTX.US) Q1 2025 Earnings Conference
Insights Into Halozyme Therapeutics's Upcoming Earnings
These Are the Sectors Best Liked Within Defensive and Cyclicals Groups – Morgan Stanley
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
TG Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results.
Axsome Therapeutics Q1 Adj. EPS $(0.68) Beats $(1.33) Estimate, Sales $121.46M Beat $119.87M Estimate
TG Therapeutics GAAP EPS of $0.03 Misses by $0.14, Revenue of $120.86M Beats by $3M
Morgan Stanley Upgrades Ascendis Pharma to Overweight, Raises Price Target to $250
Earnings Scheduled For May 5, 2025
Here's the Major Earnings Before the Open Tomorrow
Notable Healthcare Headlines for the Week: Gilead, CVS Health, Sanofi in Focus
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Ascendis Pharma Analyst Ratings
Ascendis Pharma Q1 EPS $(1.66) Misses $(1.46) Estimate, Sales $106.16M Beat $94.64M Estimate
Earnings Scheduled For May 1, 2025
A Glimpse of Ascendis Pharma's Earnings Potential